Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acrivon Therapeutics, Inc. (ACRV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Acrivon is a clinical stage biopharmaceutical company focused on precision oncology medicines developed using its Generative Phosphoproteomics AP3 platform, and its filings offer additional context on financial results, clinical programs, and business updates.
Among the documents available for ACRV are current reports on Form 8-K, which Acrivon uses to furnish press releases announcing quarterly financial results and to provide Regulation FD disclosures. For example, the company has filed 8-K reports to attach earnings press releases summarizing research and development expenses, cash and investment balances, and narrative business highlights, as well as to furnish a corporate presentation describing AP3 capabilities, synergy data for ACR-368 and ACR-2316 with immune checkpoint inhibitors, and updates to its pipeline overview.
Through this page, users can track how Acrivon reports its progress with lead programs such as ACR-368, a CHK1/CHK2 inhibitor in a registrational-intent Phase 2 or Phase 2b trial in endometrial cancer, and ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 development, along with AP3-driven preclinical initiatives. Real-time updates from EDGAR ensure that new ACRV filings, including additional 8-Ks and other periodic reports, are reflected as they become available.
Stock Titan’s interface is designed to pair these filings with AI-powered summaries that explain the key points of each document in clear language. Users can quickly see what each ACRV filing covers—such as financial condition, clinical data highlights, or platform developments—while retaining the ability to open the full SEC text for detailed review, including any exhibits like press releases or corporate presentations incorporated by reference.
Acrivon Therapeutics, Inc. Chief Accounting Officer Katharine Peterson reported a small tax-related share disposition. On the vesting of restricted stock units, 116 shares of common stock were withheld by the company to satisfy mandatory tax withholding, valued at $1.63 per share. After this withholding, Peterson directly holds 4,006 shares of Acrivon common stock.
Acrivon Therapeutics, Inc. Chief Legal Officer Mary Miller reported a routine share disposition related to taxes. On the transaction date, 217 shares of common stock were withheld by the company at a price of
Acrivon Therapeutics, Inc. Chief Development Officer Erick Gamelin reported a tax-related share disposition. On February 14, 2026, the issuer withheld 471 shares of common stock at $1.63 per share to satisfy mandatory tax withholding upon vesting of restricted stock units. This reduced Gamelin’s directly held common stock to 14,812 shares. The transaction is classified as a disposition for tax withholding, not an open-market purchase or sale.
Acrivon Therapeutics Chief Operating Officer Eric Devroe reported a small tax-related share disposition. On the vesting of restricted stock units, 723 shares of common stock were withheld by the company at a price of
Acrivon Therapeutics insiders reported tax-related share dispositions tied to restricted stock unit vesting. The filing shows 1,302 shares of Common Stock disposed at
A separate indirect transaction reports a tax-withholding disposition of 579 Common Stock shares at
Acrivon Therapeutics, Inc. insider Mary Miller, the company’s Chief Legal Officer, reported a routine share withholding related to equity compensation. On 01/17/2026, 659 shares of common stock were withheld at a price of $1.98 per share to cover mandatory tax withholding when her restricted stock units vested. After this transaction, she beneficially owned 33,896 shares of Acrivon common stock, held directly. This type of transaction does not represent an open-market sale but an automatic tax-related adjustment.
Acrivon Therapeutics’ President and CEO, Dr. Peter Blume-Jensen, reported buying 49,000 shares of common stock on January 14, 2026, in an open-market purchase at a weighted average price of $1.676 per share. The trades were executed in multiple lots at prices ranging from $1.66 to $1.68 per share. Following this transaction, he directly holds 2,095,771 common shares.
The filing also reports 314,706 common shares held indirectly through co-founder and EVP Dr. Kristina Masson. Footnotes state that Dr. Masson disclaims beneficial ownership of Dr. Blume-Jensen’s directly held shares, and Dr. Blume-Jensen likewise disclaims beneficial ownership of Dr. Masson’s shares, except to the extent of each spouse’s pecuniary interest.
Acrivon Therapeutics, Inc. Chief Financial Officer Adam D. Levy reported an open-market purchase of the company’s common stock. On January 14, 2026, he bought 8,832 shares of Acrivon common stock in a series of trades at a weighted average price of $1.6983 per share, with individual trade prices ranging from $1.695 to $1.7086. Following this transaction, he beneficially owned 20,983 shares of Acrivon common stock, held in direct ownership.
Acrivon Therapeutics, Inc. Chief Operating Officer Eric Devroe reported an open-market purchase of company stock. On 01/13/2026, he bought 10,000 shares of Acrivon common stock at a weighted average price of $1.7218 per share, executed in multiple trades within a price range of $1.719 to $1.7268. Following this purchase, he beneficially owns 75,308 shares of Acrivon common stock in direct ownership.
Acrivon Therapeutics, Inc. reported that it hosted a corporate webcast and conference call on January 8, 2026, featuring a presentation by its leadership team and an interactive Q&A session. In connection with this event, the company posted a presentation on its investor relations website titled the January 8, 2026 Data Update. This presentation includes clinical data and program updates for the ACR-368 program as well as initial clinical data for ACR-2316.
The same January 8, 2026 Data Update has been furnished as Exhibit 99.1 to this report under a Regulation FD disclosure item, and is expressly not deemed filed for liability purposes under the Exchange Act unless later specifically incorporated by reference.